OBJECTIVES: Patients with extrathoracic synchronous solitary metastasis and non-small cell lung cancer (NSCLC) are rare. The effectiveness of both tumour sites resection is difficult to evaluate because of the high variability among clinical studies. We reviewed our experience regarding the management and prognosis of these patients.
INTRODUCTION
Distant metastases from non-small cell lung cancer (NSCLC) are generally multiple and disseminated, and most of the patients with metastatic disease at presentation are not amenable to curative treatment [1, 2] . However, a recent evidence-based medicine review confirmed that the resection of both the primary and the metastatic site improves the prognosis in selected patients with NSCLC and synchronous solitary brain metastasis [3] , and three short series [1, [4] [5] [6] suggested that some patients with solitary extracranial metastasis may also benefit from resection. However, patients with extrathoracic synchronous solitary metastasis from NSCLC are very rare [1] and represent a questioning subset of patients for whom the effectiveness of surgery is difficult to evaluate because of high variability among clinical studies and patient selection bias [2] . The purpose of this study was to review our experience with NSCLC patients with extrathoracic synchronous solitary metastasis who underwent lung surgery on a curative intend and to revisit the variables of prognostic value.
PATIENTS AND METHODS

Overall population
We retrospectively reviewed the charts of every patient who underwent surgery for NSCLC between January 1983 and December 2006 in Georges Pompidou European Hospital (Paris) and Cedar Surgery Centre (Boisguillaume). Preoperative workup included chest X-ray, bronchoscopy, computed tomography (CT) scan of the chest, spirometry, lung perfusion scan and a thorough search for distant metastases [including positron emission tomography (PET) scan in recent years]. Mediastinoscopy was routinely performed to exclude N3 disease and to confirm N2 involvement in patients included in induction treatment protocols. The staging system was the International Staging System for NSCLC adopted recently modified concerning the T [7, 8] and M. N3 disease and multiple distant metastases precluded surgery. When resectable, extrathoracic synchronous solitary metastasis was not considered a contraindication to lung cancer surgery. Patients underwent thoracotomy on a curative intend and anatomical lung resection with systematic mediastinal lymph node (LN) dissection whenever feasible. Between January 1983 and December 2006, 4668 patients underwent lung surgery in a curative intent for NSCLC stages I to IV in the study centres and account for the overall population.
Study group
Among them, 94 patients (2.0% of the overall population) underwent lung surgery in a curative intent for NSCLC associated with extrathoracic synchronous solitary metastasis and account for the study group. We particularly analysed the epidemiology, pathology, metastatic location and prognosis characteristics of these patients and compared the survival of patients whose metastasis has been resected (resected subgroup) or not (unresected subgroup). The resected subgroup benefited from adjuvant treatments including chemotherapy, radiotherapy or both, according to clinical and pathologic characteristics. The unresected subgroup has been treated by radiotherapy, radiosurgery or chemoradiotherapy following standard protocols. If all patients had synchronous metastatic disease, the exact timing of resection depended on the location and the treatment of the metastasis. In the case of brain metastasis, patients beneficiated first from metastasis resection and then from primary tumour resection. In the case of adrenal, liver metastasis or bone, patients beneficiated from concomitant surgical resection, either in a unique procedure or during initial hospitalization. In the case of skin metastasis, patients have beneficiated from concomitant surgical resection during a unique procedure in all cases. When the metastasis was not amenable to surgical resection, the primary tumour was resected first, and the metastasis was then irradiated. The interval between primary tumour and metastasis treatment allowed the administration of induction chemotherapy, adjuvant chemotherapy or both and was less than 3 months in all cases.
Follow-up
Follow-up information was obtained from the hospital case records, from a questionnaire completed by the chest physician or general practitioner or from death certificates. In the overall population, mean follow-up duration was 72.8 (±48) months and 65 patients (1.3% of the overall population) were lost during follow-up. In the study group, median follow-up was 11 months (range 0-131 months). Among the patients who died during follow-up (n = 77), median follow-up was 10 months (range 0-121 months). Among the patients who were still alive at the end of the follow-up (n = 17), the median follow-up was 33 months (range 3-131 months). No patient was lost during the follow-up in the study group.
Statistical analysis
The main evaluated factor was the overall survival, defined as the time interval between the date of operation and the date of death or the last follow-up visit for censored patients. Actuarial survival curves were estimated by the Kaplan-Meier method. Univariate analyses of survival distributions were made using the log-rank test and the following outcome variables: gender, age, induction treatment, type of surgical resection, histology, tumour size and type of nodal involvement. Multivariate analysis was then performed using the Cox proportional hazards model for overall survival analysis and the same outcome variables. P < 0.05 was considered statistically significant. The software used for statistical analysis was SEM (Anticancer Centre Jean Perrin, Clermont-Ferrand, France) [9] .
Ethical concerns
This retrospective study was approved by the Thoracic Surgery Society Ethic Committee that waived the need for informed consent (number = 2010.9.25.6.32.20.RiMa).
RESULTS
Study group
The study group included 72 males and 22 females with a mean age of 56 ± 9.4 years. Lung cancer was right-sided in 57 patients and left-sided in 37. The surgical resection consisted of 27 pneumonectomies (29%), 65 lobectomies (69%) and 2 exploratory thoracotomies (2%). Histology revealed 20 squamous cell carcinomas (21%), 57 adenocarcinomas (61%), 14 undifferentiated large cell carcinomas (15%) and 3 other types of primary NSCLC (3%). The pN involvement was N0 in 46 patients (49 %), N1 in 17 patients (18%) and N2 in 31 patients (33%).
Metastatic locations
There were five groups of metastases: brain (n = 57), adrenal gland (n = 12), bone (n = 14), liver (n = 5) and skin (n = 6). The site of the bone metastasis was rib in seven patients, femur and vertebra in two and the scapula, skull and foot big toe in one each. Sixty-nine metastases were removed surgically (73%). Details concerning epidemiology, operation and operative results of each group are shown in Table 1 and pathology (including TNM) in Table 2 .
Outcome
Postoperative complications occurred in 32 patients (34%). In hospital mortality and morbidity rates were 7 and 27%, respectively. When in hospital mortality was excluded, 5-year survival rate was 16% with a median of 13 months (Fig. 1) . Five-year survival rates according to metastasis location are shown in Table 1 . Small sample size forbid direct statistical comparison between metastatic locations, but some fact may be underlined. Resection of hepatic or bone metastasis was never associated with longterm survival, even when the bone metastasis was on the rib close to the thoracotomy level. Resection of solitary cutaneous metastasis was associated with long-term survival in 3 cases. Solitary synchronous brain and adrenal metastasis, resected or not, were associated with 5-year survival rates of 12 and 22%, respectively.
Prognostic factors
Univariate analysis demonstrated that induction treatment (Fig. 2b) , tumour size, nodal involvement (Fig. 2a) , type of parenchymatous resection and histology were significant prognostic factors, but surgical resection of the metastasis was not (Table 3) . Multivariate analyses demonstrated that younger age, induction treatment, small size of the lung tumour, N0 status and adenocarcinoma histology were associated with a better prognosis, but surgical resection of the metastasis was not (Table 4) , even when considering the larger group of brain metastases (surgical resection n = 46, 5-year survival 13%, median 15 months, vs. no resection n = 10, 5-year survival 13% median 16 months, P = 0.79).
COMMENTS
In this study, NSCLC with extrathoracic synchronous solitary metastasis may benefit from lung and metastasis resection on a curative intend, and long-term survival is achievable in patients with brain, adrenal or cutaneous metastasis. However, prognosis analysis failed to find a favourable impact of metastasis resection on 5-year survival. Among 67 731 patients reviewed for the IASLC lung cancer staging project, 6596 had metastatic disease (9.7%); among them 671 had pleural dissemination (malignant pleural effusion or pleural nodules), and 5925 distant systemic metastases, which is 89.8% of the patients with metastases [10] . These haematogenous metastases are now termed M1b in the new TNM classification [7] . Most patients with M1b disease have multiple sites of metastases, and their survival is measured in months despite chemotherapy [1] . Synchronous solitary metastasis is extremely rare, representing 2% of this standard surgical series of NSCLC patients and <0.7% of a similar series submitted to systematic [18F] fluorodeoxyglucose (FDG) PET imaging during staging workup [6] .
The most common extrapulmonary sites of distant metastases are the brain, bone, liver and adrenal gland [11] . We observed solitary metastasis with high frequency in the same organs and in the skin, but they were exceptionally observed anywhere in other series: kidney, axillary LN, spleen and colon [1, 4] .
Brain metastases are the most frequent, representing 60% of solitary metastases in this and other series [4, 6] , and the first series demonstrating benefit on survival of combined resection of primary and solitary M1b was not surprisingly concerning brain metastasis [12] . An evidence-based medicine review confirmed that the resection of both the primary and the brain metastasis improved the prognosis in selected patients [3] , including the absence of LN involvement, adenocarcinoma subtype and positive response to induction chemotherapy. The other most frequently published series of patients concerns solitary adrenal gland metastasis. Solitary adrenal metastasis may be observed in many primaries: NSCLC represents only 17% of them but is the one with the worst prognosis [13] . Factors of better prognosis are the same as those mentioned in the case of brain metastasis [14] , but synchronous adrenal metastasis may represent per se a factor of poorer prognosis [15] , so probably explaining the poor median survival in these patients. The presence of the liver, bone or skin metastasis is a condition still more commonly considered as a sign of an inoperable disease, and we effectively did not observe a 5-year survivor in cases with liver and bone solitary metastasis, but surgery offered a chance of cure in some patients with resected skin metastasis.
Regardless the metastasis location, long-term survivors were mainly presenting NSCLC with N0 staging, adenocarcinoma subtype and some degree of chemotherapy responsiveness, and these three factors need further considerations.
The absence of clinical lymph node involvement is a basic condition for performing both metastasis and lung resection, but is never entirely confirmed: N2 disease proved to be present in 33% of the patients in this series, in 22% of Ambrogi et al.'s patients [1] and in 40% of De Pas et al.'s patients [6] . Furthermore, in the latter series FDG-PET scan and spiral CT were routinely performed in the preoperative workup; mediastinoscopy was performed in all patients with ipsilateral mediastinal nodes 1 cm or greater in size in their short-axis diameter on a CT scan or positive on an FDG-PET scan; despite this, three fourth of patients with N2 disease had occult mediastinal LN involvement. N1 solitary metastasis shares the same poor prognosis value and is also frequent: 18.1% in this series, 22.2 and 10% in the others [1, 6] . Solitary pN0 metastasis is thus confirmed in only half of the patients and is a still rarer entity than solitary cN0 metastasis, whose better prognosis might be explained by a more favourable biological behaviour.
Adenocarcinoma histology is the histological subset most frequently encountered: 60.6% in this series, 73.9% in Downey et al.'s series [4] and 80% in De Pas et al.'s series [6] . Adenocarcinoma is a large spectrum of different histology patterns with different prognostic value [16] , and this might also indicate that curable solitary metastasis could have a more favourable histology-related biological behaviour.
The third factor of good prognosis is related to induction chemotherapy. A phase II trial of chemotherapy and surgery concluded that overall survival was not superior with that treatment strategy in such patients [4] , but retrospective studies are commonly supporting that prognosis might be ameliorated by induction therapy, which was also significant in this series. However, retrospective studies include patients who actually underwent surgical resection of their primary tumour and metastasis and excluded patients whose disease progress while on induction chemotherapy. Therefore, beside unproved intrinsic efficacy, induction chemotherapy protocols may perform a strong selection of indolent tumour suitable for surgical resection and amenable to a better prognosis when studied retrospectively.
Beside selection bias, this study failed to demonstrate the advantage of surgical resection over non-surgical local treatments (i.e. radiotherapy of adrenal metastasis, radiosurgery of brain metastasis). This negative result may be due to the small number of patients in this study, inducing a weak power. However, this result is in line with a recent report by Oshiro et al. [17] , observing a 5-year survival rate of 22%, in patients treated with radiotherapy for local control of asymptomatic adrenal metastasis. These results question the validity of commonly acknowledged gold standard that preaches systematic resection of solitary synchronous metastasis in the case of resectable N0 or N1 lung adenocarcinoma amenable to lobectomy. A solitary metastasis in pN0 NSCLC patient is possibly a 'low-grade' tumour that may also be treated by radiotherapy or controlled by systemic chemotherapy, except for symptomatic lesions where surgery is still considered the treatment of choice.
However, this study has several limitations, including its retrospective design, the heterogeneity of patients' population over a 23-year period and the low number of patients in some subgroups. In particular, induction treatment may lead to a selection bias, with progressive diseases being excluded from surgical resection of the primary tumour, and to the confusion of the respective role of induction treatment and metastasis local treatment on overall survival. With respect to these limitations, this study confirms the conclusions of the literature review of Pfannschmidt and Dienemann [2] on the surgical treatment of oligometastatic NSCLC, stressing the impossibility to precisely distinguish between the relative contributions of tumour biology, surgery, radiotherapy or systemic therapy on long-term survival of these patients.
CONCLUSIONS
NSCLC patients with synchronous solitary brain, adrenal or cutaneous metastasis may benefit from lung resection on a curative intend in the case of adenocarcinoma and N0 extension whose complete resection is achievable with a lobectomy. However, prognosis analysis failed to find a favourable impact of metastasis resection on 5-year survival, questioning the superiority of resection over radio and/or chemotherapy as the treatment of choice of solitary synchronous M1b metastasis. Regarding the common belief over this indication, further multicentric studies must be considered to show the real benefit of this accepted point of view.
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